ConductScience.org, home

Paper11675350

Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species.

Bellosillo B and 7 others. Blood, 2001. Cited by 166 papers, by iCite.

Cite this record

ConductScience Library. Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species. Papers, record 11675350. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/11675350

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species.
PubMed
Journal
Blood
PubMed
Year
2001
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
166
iCite
Relative citation ratio, by iCite
3.35
iCite
Revised in PubMed
2022-03-09
PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Bellosillo BB
2Villamor NN
3López-Guillermo AA
4Marcé SS
5Esteve JJ
6Campo EE
7Colomer DD
8Montserrat EE

Source PubMed

Download CSV of authors

Topics21

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antibodies, MonoclonalMajor topic
B-LymphocytesMajor topic
CaspasesMajor topic
Cell DeathMajor topic
Complement System ProteinsMajor topic
Lymphoproliferative DisordersMajor topic
Reactive Oxygen SpeciesMajor topic
Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal, Murine-Derived
Antigens, CD20
Antineoplastic Agents
CD55 Antigens
CD59 Antigens
Dose-Response Relationship, Drug
Female
Humans
Male
Middle Aged
Rituximab

Source PubMed

Download CSV of topics

Cited by67

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 166 citations.

PMIDTitleJournalYearIn PapersSource
42426484The pharmacokinetics and its covariates of rituximab in different clinical populations: a systematic review and narrative synthesis.Eur J Clin Pharmacol2026https://conductscience.org/library/papers/42426484PubMed
41909695Selection of laboratory assays for reliable assessment of complement-dependent cytotoxicity: impact of assay choice on CDC quantification.Front Immunol2026https://conductscience.org/library/papers/41909695PubMed
41469420Novel anti-ITGA4 monoclonal antibody induces cell death via large pore formation in NK/T-cell lymphoma cells.Sci Rep2025https://conductscience.org/library/papers/41469420PubMed
40576254Pharmacokinetic Characterization of Rituximab in Patients with Glomerular Diseases.Ther Drug Monit2025https://conductscience.org/library/papers/40576254PubMed
38671922Potential New Therapies "ROS-Based" in CLL: An Innovative Paradigm in the Induction of Tumor Cell Apoptosis.Antioxidants (Basel)2024https://conductscience.org/library/papers/38671922PubMed
36968995The protective role of the microenvironment in hairy cell leukemia treatment: Facts and perspectives.Front Oncol2023https://conductscience.org/library/papers/36968995PubMed
35147819Advancing Biologic Therapy for Refractory Autoimmune Hepatitis.Dig Dis Sci2022https://conductscience.org/library/papers/35147819PubMed
33198328Radioprotective Agents and Enhancers Factors. Preventive and Therapeutic Strategies for Oxidative Induced Radiotherapy Damages in Hematological Malignancies.Antioxidants (Basel)2020https://conductscience.org/library/papers/33198328PubMed
32255851Cytotoxic Effect of Prodigiosin, Natural Red Pigment, Isolated from Serratia marcescens UFPEDA 398.Indian J Microbiol2020https://conductscience.org/library/papers/32255851PubMed
30962539Surfaceome interrogation using an RNA-seq approach highlights leukemia initiating cell biomarkers in an LMO2 T cell transgenic model.Sci Rep2019https://conductscience.org/library/papers/30962539PubMed
30655772Effects of complement and serum IgG on rituximab-dependent natural killer cell-mediated cytotoxicity against Raji cells.Oncol Lett2019https://conductscience.org/library/papers/30655772PubMed
30504310Novel immunotherapy approaches to follicular lymphoma.Hematology Am Soc Hematol Educ Program2018https://conductscience.org/library/papers/30504310PubMed
30308958Molecular Markers of Anticancer Drug Resistance in Head and Neck Squamous Cell Carcinoma: A Literature Review.Cancers (Basel)2018https://conductscience.org/library/papers/30308958PubMed
30096012Anti-CD20 monoclonal antibodies: reviewing a revolution.Hum Vaccin Immunother2018https://conductscience.org/library/papers/30096012PubMed
29770165Targeting Oxidatively Induced DNA Damage Response in Cancer: Opportunities for Novel Cancer Therapies.Oxid Med Cell Longev2018https://conductscience.org/library/papers/29770165PubMed
28698765Reactive Oxygen Species-Mediated Mechanisms of Action of Targeted Cancer Therapy.Oxid Med Cell Longev2017https://conductscience.org/library/papers/28698765PubMed
28213834Molecular Simulation of Receptor Occupancy and Tumor Penetration of an Antibody and Smaller Scaffolds: Application to Molecular Imaging.Mol Imaging Biol2017https://conductscience.org/library/papers/28213834PubMed
27069950Preclinical safety, pharmacokinetics, pharmacodynamics, and biodistribution studies with Ad35K++ protein: a novel rituximab cotherapeutic.Mol Ther Methods Clin Dev2016https://conductscience.org/library/papers/27069950PubMed
26283682Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy.Clin Cancer Res2016https://conductscience.org/library/papers/26283682PubMed
25859860Role of complement and complement regulatory proteins in the complications of diabetes.Endocr Rev2015https://conductscience.org/library/papers/25859860PubMed

See all 67 cited byDownload CSV of cited by

Genes4

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CASP3836PubTator's text mininghttps://conductscience.org/library/genes/836NCBI Gene
CD59966PubTator's text mininghttps://conductscience.org/library/genes/966NCBI Gene
KRT2054474PubTator's text mininghttps://conductscience.org/library/genes/54474NCBI Gene
PARP1142PubTator's text mininghttps://conductscience.org/library/genes/142NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/11675350

GET https://conductscience.org/api/papers/v1/11675350/cited_by?page=2